Comment & Response |

Glucagon-like Peptide 1–Based Drugs and Pancreatic Safety—Reply

Sonal Singh, MD, MPH1
[+] Author Affiliations
1Department of Medicine and the Center for Public Health and Human Rights, Johns Hopkins University Schools of Medicine and Public Health, Baltimore, Maryland
JAMA Intern Med. 2013;173(19):1843-1844. doi:10.1001/jamainternmed.2013.8128.
Text Size: A A A
Published online


In Reply Brodovicz et al misinterpret the results from previous studies as being inconsistent with our study.1 The meta-analysis of clinical trials of dipeptidyl peptidase-4 (DPP-4) inhibitors by Monami et al2 was underpowered through poor ascertainment or exclusion of subclinical levels of enzyme elevations. The authors did not report an optimal information size analysis, a necessary requirement for meta-analysis of drug safety that claim no risk.3 Despite these limitations, the results of the meta-analysis could not rule as much as a 73% increased risk of acute pancreatitis—a clinically significant excess hazard, which is not dissimilar to the statistically and clinically significant excess risk of more than 2-folds in our study. Similarly, the observational study by Garg et al4 could not rule out as much a 50% increased risk of acute pancreatitis with exenatide and 30% increased risk of acute pancreatitis with sitagliptin. These differences in magnitude are possible owing to differences in study design and populations, but the direction of effect has been consistently increased in all studies.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





October 28, 2013
Kimberly G. Brodovicz, DrPH; Samuel S. Engel, MD; Nancy A. Thornberry, BS
1Merck Sharp & Dohme Corporation, Whitehouse Station, New Jersey
JAMA Intern Med. 2013;173(19):1842-1843. doi:10.1001/jamainternmed.2013.8138.
October 28, 2013
Emanuel Raschi, MD, PhD; Carlo Piccinni, PharmD, PhD; Giulio Marchesini, MD, PhD
1Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
JAMA Intern Med. 2013;173(19):1843. doi:10.1001/jamainternmed.2013.8150.
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...